Recothrom Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing use of thrombin in surgical procedures, growing adoption in vascular and orthopedic surgeries, availability of recombinant protein technologies, expansion of hospital surgical capacities, rising focus on localized bleeding control.

The growth in the forecast period can be attributed to increasing demand for plasma-free hemostatic solutions, rising focus on infection risk reduction, expansion of emergency and trauma care services, growing adoption in ambulatory surgery centers, increasing investment in recombinant biologics manufacturing. Major trends in the forecast period include increasing adoption of recombinant hemostatic agents, rising use of topical thrombin products, growing demand for rapid surgical bleeding control, expansion of hemostats in trauma care, enhanced focus on biologic safety and purity.

The increase in surgical procedures is expected to drive the growth of the recothrom market going forward. Surgical procedures are medical operations performed by surgeons to diagnose or treat health conditions, often involving incisions, tissue repair or removal, or the use of instruments to correct bodily issues. The rise in surgical procedures is fueled by the growing prevalence of chronic diseases, an aging population, and advancements in medical technology, including minimally invasive techniques, which improve patient outcomes and encourage more surgeries. Recothrom aids in controlling bleeding during surgery by promoting clot formation and enhancing the body’s natural coagulation process for faster hemostasis. For instance, in August 2024, according to the National Library of Medicine, a US-based biomedical library, the global volume of aesthetic procedures increased by 3.4% in 2023, totaling 34.9 million surgical and nonsurgical procedures performed by plastic surgeons. This included over 15.8 million surgical procedures and more than 19.1 million nonsurgical treatments worldwide. Therefore, the increase in surgical procedures is driving the growth of the recothrom market.

The rise in healthcare investments is expected to support the growth of the recothrom market going forward. Healthcare investments involve allocating financial resources to the healthcare sector to support growth in areas such as medical research, healthcare services, pharmaceuticals, biotechnology, and medical technology. The increase in healthcare investments is driven by factors including an aging population, technological advancements, rising healthcare costs, and growing demand for innovative treatments and services. Such investments support recothrom by providing a recombinant thrombin solution that enhances surgical outcomes and minimizes complications, making it a valuable tool in medical procedures. For instance, in November 2025, the Organisation for Economic Co-operation and Development (OECD), a France-based intergovernmental organization, reported that in 2024, average health spending in OECD countries reached nearly USD 6,000 per capita, adjusted for purchasing power differences. Therefore, rising healthcare investments are driving the growth of the recothrom market.

Major companies in the recothrom market are focusing on innovative solutions, such as flowable hemostats, to meet the demand for faster, safer, and more efficient surgical bleeding control. Flowable hemostats are gel-based agents designed to conform to complex anatomical areas where traditional methods may be less effective. For instance, in April 2023, Baxter International Inc., a US-based healthcare company, launched Floseal + Recothrom, an advanced flowable hemostat. The product combines a flowable gelatin-based matrix with recombinant thrombin produced using recombinant DNA technology, eliminating the need for human blood components and improving safety. The formulation allows for faster preparation - over 1.5 times quicker than traditional agents - while enhancing hemostasis efficiency during surgical procedures.

Major companies operating in the recothrom market are Baxter International Inc.

North America was the largest region in the recothrom market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recothrom market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recothrom market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the recothrom market by increasing costs for imported recombinant proteins, fermentation equipment, purification systems, sterile packaging materials, and temperature-controlled logistics. Hospitals and surgical facilities in North America and Europe are most affected due to reliance on advanced biologics supply chains, while Asia-Pacific faces higher import-related costs for recombinant therapeutics. These tariffs are elevating procurement costs and influencing hospital purchasing decisions. However, they are also supporting domestic biologics manufacturing, local recombinant production investments, and regional supply chain resilience initiatives.

The recothrom market research report is one of a series of new reports that provides recothrom market statistics, including recothrom industry global market size, regional shares, competitors with a recothrom market share, detailed recothrom market segments, market trends and opportunities, and any further data you may need to thrive in the recothrom industry. This recothrom market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Recothrom is a recombinant thrombin product used during surgeries to control bleeding by promoting clot formation. As a topical hemostat, it helps stop bleeding in a localized area and is commonly applied in procedures where bleeding is likely, including vascular, liver, and orthopedic surgeries.

The primary indications for Recothrom are surgical procedures and trauma management. Surgical procedures involve medical operations performed to treat or diagnose conditions through incisions or specialized instruments. Recothrom is available in powder and solution forms and is distributed through direct sales, distributors, and online channels, serving end users such as hospitals, ambulatory surgical centers, and tactical combat casualty care settings.

The recothrom market consists of sales of surgical hemostats, hemostatic sponges, fibrin sealants, single-dose vials, and lyophilized powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.